Publication | Open Access

Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease

Single High-dose EtoposidePoor-prognosis HodgkinLymphoid NeoplasiaCell TherapyOncologyMarrow TransplantationBone Marrow FailurePrimary TherapyImmunologyHematologyStem Cell TransplantationRadiation OncologyMedicineCell TransplantationHealth Sciences